literature

HIV mutation literature information.

Structure-based methods to predict mutational resistance to diarylpyrimidine non-nucleoside reverse transcriptase inhibitors.

PMID: 29156381 2018 Journal of molecular graphics & modelling

Abstract: Consistent with previous studies, mutation K101P is predicted to confer high-level resistance to DAPYs.

Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa.

PMID: 29566538 2018 Antiviral chemistry & chemotherapy

Introduction: HIV-1LAI with different, single NNRTI mutants maintained susceptibility to RPV, except for HIV-1 with Y181I and the double mutant K101P/V179I.

Introduction: In vitro analyses of

Figure: FC resistance was evaluated based on the contribution of the number of RPV-associated mutations (L100I, K101E/P, E138A/G/K/Q/R, V179L, Y181C/I/V, Y188L, H221Y, F227C and M230I/L) per sample with and without K103N.

High prevalence of HIV-1 transmitted drug resistance among therapy-naive Burmese entering travelers at Dehong ports in Yunnan, China.

PMID: 29739342 2018 BMC infectious diseases

Result: For NNRTI resistance-associated mutations, V179D/T was identified as the major mutation (20 cases), and the other 6 types of mutation were E138A, A98G, K101P, K103 N, Y181H and Y188H.

Detection of minority drug resistant mutations in Malawian HIV-1 subtype C-positive patients initiating and on first-line antiretroviral therapy.

PMID: 29977795 2018 African journal of laboratory medicine

Result: The common minority NNRTI mutations detected were V106M, V179T and G190A (3/20 each), followed by E138K and Y181C (2/20 each), and K101P, K103N, V108I, E138A, V179D, A190E and H221Y (1/20 each).

Table: K101P

Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial.

PMID: 30513108 2018 PLoS medicine

Abstract: At 48 weeks, the nucleoside reverse transcriptase inhibitor (NRTI) mutation K219E/Q (p = 0.004) and the non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations K101E/P (p = 0.03) and P225H (p = 0.007) were less common in virus from participants with raltegravir-intensified ART, with weak evidence of less interm

Discussion: Despite similar rates of virological failure >=1,000 copies/mL, raltegravir-intensified ART was associated with lower rates of the NRTI mutation K219E/Q and the NNRTI mutations K101E/P and P225H.

Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).

PMID: 28891788 2017 HIV clinical trials

Method: Primary NNRTI-R substitutions assessed were V90I, A98G, L100I, K101E/H/P, K103N/S, V106A/I/M, V108I, E138A/G/K/Q/R, V179D/F/L/T, Y181C/I/V, Y188C/H/L, G190A/E/Q/S, H221Y, P225H, F227C, and M230I/L in RT.

High level of HIV-1 drug resistance mutations in patients with unsuppressed viral loads in rural northern South Africa.

PMID: 28750647 2017 AIDS research and therapy

Result: More than half of these mutations (K65R, D67N, K70R, L74V, V75I/S, Y115F, K219Q/E, K101E/P/H, K103N, V106AM, Y181C and Y188L/H) were significantly more prevalent (p < 0.05) in the rural settings of Limpopo than in urban Pretoria (Table 2).

HIV-1 viraemia and drug resistance amongst female sex workers in Soweto, South Africa: A cross sectional study.

PMID: 29244809 2017 PloS one

Table: K101P

Systematic review to determine the prevalence of transmitted drug resistance mutations to rilpivirine in HIV-infected treatment-naive persons.

PMID: 26761642 2016 Antiviral therapy

Abstract: Rilpivirine mutations assessed were: L100I, K101E/P, E138A/G/K/Q/R, V179L, Y181C/I/V, Y188L, H221Y, F227C and M230I/L.

Q148N, a Novel Integrase Inhibitor Resistance Mutation Associated with Low-Level Reduction in Elvitegravir Susceptibility.

PMID: 27009474 2016 AIDS research and human retroviruses

Introduction: A baseline genotypic resistance test revealed the nucleoside reverse transcriptase inhibitor-resistance mutations L210W and T215D that were interpreted as causing intermediate resistance to zidovudine and low-level resistance to tenofovir; the non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistance mutations K101P and K103S that were interpreted as causing high-level resistance to each of the NNRTIs; and the protease inhibitor-resistance mutations D30N, L33F, I54V, N88D, and L90M

Browser Board

Co-occurred Entities

Filtrator